Navigation Links
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Date:6/12/2008

- APD125 Significantly Improved Key PSG Parameters of Sleep Maintenance -

- Phase 2b Subjective Study Ongoing -

SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Dr. Thomas Roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinical trial of APD125 for the treatment of insomnia in an oral presentation at the SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies in Baltimore, Maryland.

APD125 is an oral drug candidate discovered by Arena that is being evaluated for the treatment of insomnia in patients who have difficulty maintaining sleep after initial sleep onset. When compared to placebo in the Phase 2a clinical trial, patients treated with APD125 experienced statistically significant improvements in polysomnographic (PSG) measurements of sleep maintenance, or the ability to maintain sleep during the night after falling asleep. These improvements were achieved without any next day impairment of cognition or coordination.

"APD125 is a potential next generation treatment for improving sleep maintenance that could meet the needs of many patients looking to achieve better 'quality sleep'," stated Dr. Thomas Roth of Henry Ford Hospital, who interpreted the PSG data for the Phase 2a trial. "In the trial, APD125 clearly demonstrated robust sleep maintenance properties without any apparent pattern of side effects associated with the drug."

Arena is currently evaluating the effects of APD125 on patients' subjective assessment of sleep in a Phase 2b study.

APD125 Phase 2a Study Results

In a Phase 2a clinical trial, APD125 significantly improved several PSG endpoints measuring improve
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
4. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
5. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
7. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... December 15, 2014 Investor-Edge has initiated ... ZGNX ), Eli Lilly and Company (NYSE: LLY ... SNY ), and Novartis AG (NYSE: ... accessed at: http://investor-edge.com/register . On Friday, December ... the Dow Jones Industrial Average lost 1.79%, to finish the ...
(Date:12/15/2014)... LONDON and BOSTON , ... the leading GPCR structure-guided drug discovery and development company, ... patents in the United States ... of these patents in the US significantly strengthens the ... the major pharmaceutical markets. The suite of ...
(Date:12/13/2014)... Ala. , Dec. 12, 2014 ... purchased the HiSeq X Ten sequencing system manufactured ... enable HudsonAlpha to produce and analyze genomic data ... stems from the Institute,s commitment to research programs ... The HiSeq X Ten provides unprecedented capacity, speed ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... YORK, April 20, 2011 Reportlinker.com announces that a ... Successful Strategies for Drug Repositioning ... Introduction This report Highlights ... to drug development. The success of the approach is ...
... Sagent Pharmaceuticals (Nasdaq: SGNT ) announced the ... of the offering has been increased from the previously announced ... stock at a price to the public of $16.00 per ... NASDAQ Global Market on April 20, 2011 under the ticker ...
Cached Medicine Technology:Reportlinker Adds Successful Strategies for Drug Repositioning 2Reportlinker Adds Successful Strategies for Drug Repositioning 3Reportlinker Adds Successful Strategies for Drug Repositioning 4Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering 2
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, ... approaching, a new study reveals that states that routinely perform ... drivers on their roads. The finding suggests that states ... to deter inebriated revelers from getting behind the wheel in ... passed regarding drinking and driving," said study lead author James ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device ... North and South America, Europe, the Middle East, Asia ... for its 2015 Medical Device Industry Survey. Each year, ... business and market trends as well as regulatory and ... areas including:, , Overall prospects for ...
(Date:12/15/2014)... For the second year in a row, ... Coffees of 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak ... at number 10. This is the first year that any ... is ranked on quality, value, and other aspects, including certifications ... of 100, and at $17.99 for 12-ounces, was also the ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... CHAPEL HILL -- When pregnant women are at high risk ... has been shown to reduce the babys chances of having ... multiple injections of corticosteroids, and a new study shows that ... of cerebral palsy among children of these mothers. , Our ...
... the great questions of neurobiology, how the brain is ... a young French scientist in an award winning project ... European Heads of Research Councils (EuroHORCS). Sonia Garel ... annually to young scientists, to pursue her ground breaking ...
... to low-glycemic carbs prevents the lethal illness, study finds ... in quick-burning carbohydrates may cause fatty liver disease, which ... a study in mice by researchers at Children,s Hospital ... it may mean that fatty liver disease can be ...
... New guidelines on the diagnosis and management of cows ... Disease in Childhood, are set to improve the standard ... food allergy in children.1 The Guidelines for the Diagnosis ... extensively hydrolysed (eHF) and amino acid-based formulas (AAF), and ...
... been awarded a National Institutes of Health (NIH) Directors ... is one of 12 recipients nationwide to win the ... award is designed to support individual scientists of exceptional ... biomedical and behavioral research. The term pioneering is used ...
... the review of approximately 12,000 emergency diagnostic imaging exams ... the midst of our research, a vigorous national debate ... prior to independent call, said Richard B. Ruchman, MD, ... and subsequently approved a new requirement that would mandate ...
Cached Medicine News:Health News:Multiple corticosteroid injections in pregnant women may increase cerebral palsy 2Health News:EURYI project to understand how the brain wires during embryogenesis 2Health News:Diet Change Can Curb Fatty Liver Disease 2Health News:New guidelines set to improve standard of cows' milk allergy care 2Health News:New guidelines set to improve standard of cows' milk allergy care 3Health News:Decision-making by residents on-call has 'miniscule' negative impact on patient care 2
... is a hospital grade Nd: YAG laser ... precise, reliable means for performing posterior capsulotomy, ... can be used for the treatment of ... (posterior capsulotomy), and closed-angle glaucoma (iridotomy). , ...
... Laserex Ultra Q is the fundamental capsulotmy laser ... energy delivery and provides 2855% less energy in ... mJs in contemporary systems. This technology eliminates ... the risk of IOL pitting. , , ...
... a high-end, mobile ultrasound imaging system. Its ... tremendous amount of processing power for generating ... Ultrasonix imaging systems provide excellent image quality ... Pulsed Doppler, Color Doppler Color Angio, Color ...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
Medicine Products: